Although pituitary tumours are relatively uncommon, their association with menstrual irregularity and infertility brings them into the domain of obstetrics and gynaecology. This review addresses the range of pituitary tumours with particular regard to diagnosis, growth and behaviour and management during pregnancy.
Get full access to this article
View all access options for this article.
References
1.
GonzalezJG, ElizondoG, SaldivarD, NanezH, ToddLE, VillarrealJZ. Pituitary gland growth during normal pregnancy: an in vivo study using magnetic resonance imaging.Am J Med1988; 85: 217–20
MolitchME. Pituitary tumors and pregnancy.Growth Horm IGF Res2003; 13(Suppl. A):S38–44
4.
CasanuevaFF, MolitchME, SchlechteJA. Guidelines of the Pituitary Society for the diagnosis and management of prolactinomas.Clin Endocrinol (Oxf)2006; 65: 265–73
5.
MolitchME. Management of prolactinomas during pregnancy.J Reprod Med1999; 44(Suppl):1121–6
6.
BigazziM, RongaR, LancranjanI. A pregnancy in an acromegalic woman during bromocriptine treatment: effects on growth hormone and prolactin in the maternal, fetal, and amniotic compartments.J Clin Endocrinol Metab, 1979; 48: 9–12
7.
RaymondJP, GoldsteinE, KonopkaP, LeleuMF, MerceronRE, LoriaY. Follow-up of children born of bromocriptine-treated mothers.Horm Res1985; 22: 239–46
8.
US Food, and Drug Administration. FDA Moves to End Use of Bromocriptine for Postpartum Breast Engorgement. FDA Talk Paper 1994: T94-37
9.
Jong-de van den BergL, MintzesB. Bromocriptine and lactation suppression: are the risks acceptable?Pharm World Sci1995; 17: 93–5
10.
LoeweC, DragovicLJ. Acute coronary artery thrombosis in a postpartum woman receiving bromocriptine.Am J Forensic Med Pathol1998; 19: 258–60
11.
RobertE, MusattiL, PiscitelliG, FerrariCI. Pregnancy outcome after treatment with the ergot derivative, cabergoline.Reprod Toxicol1996; 10: 333–7
12.
ColaoA, AbsR, BarcenaDG, ChansonP, PaulusW, KleinbergDL. Pregnancy outcomes following cabergoline treatment: extended results from a 12-year observational study.Clin Endocrinol (Oxf)2008; 68: 66–71
13.
WebsterJ. A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation.Drug Saf1996; 14: 228–38
14.
SchadeR, AndersohnF, SuissaS, HaverkampW, GarbeE. Dopamine agonists and the risk of cardiac-valve regurgitation.N Engl J Med2007; 356: 29–38
15.
ZanettiniR, AntoniniA, GattoG, GentileR, TeseiS, PezzoliG. Valvular heart disease and the use of dopamine agonists for Parkinson's disease.N Engl J Med2007; 356: 39–46
16.
Medicines and Healthcare Products Regulatory Agency. Drug safety update 2008; 2
17.
Newman-TancrediA, CussacD, QuentricY. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-HT(2), receptor subtypes.J Pharmacol Exp Ther2002; 303: 815–22
MolitchME. Pregnancy and the hyperprolactinemic woman.N Engl J Med1985; 312: 1364–70
20.
ChengS, GrassoL, Martinez-OrozcoJA. Pregnancy in acromegaly: experience from two referral centers and systematic review of the literature.Clin Endocrinol (Oxf)2012; 76: 264–71
21.
ErikssonL, FrankenneF, EdenS, HennenG, Von SchoultzB. Growth hormone 24-h serum profiles during pregnancy - lack of pulsatility for the secretion of the placental variant.Br J Obstet Gynaecol1989; 96: 949–53
22.
BeckersA, StevenaertA, FoidartJM, HennenG, FrankenneF. Placental and pituitary growth hormone secretion during pregnancy in acromegalic women.J Clin Endocrinol Metab1990; 71: 725–31
23.
CaronP, BroussaudS, BertheratJ. Acromegaly and pregnancy: a retrospective multicenter study of 59 pregnancies in 46 women.J Clin Endocrinol Metab2010; 95: 4680–7
QureshiA, KaluE, RamanathanG, BanoG, CroucherC, PanahlooA. IVF/ ICSI in a woman with active acromegaly: successful outcome following treatment with pegvisomant.J Assist Reprod Genet2006; 23: 439–42
26.
BrianSR, BidlingmaierM, WajnrajchMP, WeinzimerSA, InzucchiSE. Treatment of acromegaly with pegvisomant during pregnancy: maternal and fetal effects.J Clin Endocrinol Metab2007; 92: 3374–7
27.
LindsayJR, JonklaasJ, OldfieldEH, NiemanLK. Cushing's syndrome during pregnancy: personal experience and review of the literature.J Clin Endocrinol Metab2005; 90: 3077–83
28.
CarrBR, ParkerCRJr, MaddenJD, MacDonaldPC, PorterJC. Maternal plasma adrenocorticotropin and cortisol relationships throughout human pregnancy.Am J Obstet Gynecol1981; 139: 416–22
29.
MellorA, HarveyRD, PobereskinLH, SneydJR. Cushing's disease treated by trans-sphenoidal selective adenomectomy in mid-pregnancy.Br J Anaesth1998; 80: 850–2
30.
VilarL, Freitas MdaC, LimaLH, LyraR, KaterCE. Cushing's syndrome in pregnancy: an overview.Arq Bras Endocrinol Metabol2007; 51: 1293–302
31.
ConnellJM, CordinerJ, DaviesDL, FraserR, FrierBM, McPhersonSG. Pregnancy complicated by Cushing's syndrome: potential hazard of metyrapone therapy. Case report.Br J Obstet Gynaecol1985; 92: 1192–5
BerwaertsJ, VerhelstJ, MahlerC, AbsR. Cushing's syndrome in pregnancy treated by ketoconazole: case report and review of the literature.Gynecol Endocrinol1999; 13: 175–82
34.
HansonTJ, BallonoffLB, NorthcuttRC. Letter: Amino-glutethimide and pregnancy.JAMA1974; 230: 963–4
35.
LeibaS, WeinsteinR, ShindelB. The protracted effect of o, p’-DDD in Cushing's disease and its impact on adrenal morphogenesis of young human embryo.Ann Endocrinol (Paris)1989; 50: 49–53
36.
KnappeG, GerlH, VentzM, RohdeW. [The long-term therapy of hypothalamic-hypophyseal Cushing's syndrome with mitotane (o, p’-DDD)].Dtsch Med Wochenschr1997; 122: 882–6
37.
ChaiamnuayS, MosterM, KatzMR, KimYN. Successful management of a pregnant woman with a TSH secreting pituitary adenoma with surgical and medical therapy.Pituitary2003; 6: 109–13
38.
BlackhurstG, StrachanMW, CollieD, GregorA, StathamPF, SecklJE. The treatment of a thyrotropin-secreting pituitary macroadenoma with octreotide in twin pregnancy.Clin Endocrinol (Oxf)2002; 57: 401–4
39.
CaronP, GerbeauC, PradayrolL, SimonettaC, BayardF. Successful pregnancy in an infertile woman with a thyrotropin-secreting macroadenoma treated with somatostatin analog (octreotide).J Clin Endocrinol Metab1996; 81: 1164–8
40.
KaravitakiN, CollisonK, HallidayJ. What is the natural history of nonoperated nonfunctioning pituitary adenomas?Clin Endocrinol (Oxf)2007; 67: 938–43
41.
MasdingMG, LeesPD, Gawne-CainML, SandemanDD. Visual field compression by a non-secreting pituitary tumour during pregnancy.J R Soc Med2003; 96: 27–8
42.
KupersmithMJ, RosenbergC, KleinbergD. Visual loss in pregnant women with pituitary adenomas.Ann Intern Med1994; 121: 473–7
